NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
American Society of Hematology (ASH) 2016 – Poster
Discovery and preclinical development of novel CD74-targeting antibody-drug conjugates (ADCs) with significant activity in multiple myeloma (MM) cell lines and xenograft models 2016 DEC ASH MM Poster final no logo
BioTech Nation Radio with CEO Bill Newell
NPR and BioTech Nation interview Sutro's CEO William Newell to learn more about the next generation of cancer therapeutics. Click here to listen to the conversation as Bill describes Sutro's discovery and development efforts combining targeted warheads and ADC's in...
Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma
SAN FRANCISCO, Sept. 19, 2016 -- Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it developed to target CD74, a protein highly expressed in hematologic malignancies. The...
Sutro Marks Important Progress — Receives Two Milestone Payments from Celgene
SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation (Celgene) for achievements in preclinical development and manufacturing under the company's...
Sutro Appoints Shabbir T. Anik Chief Technical Operations Officer
SOUTH SAN FRANCISCO, June 1, 2016 – Sutro Biopharma today announced the appointment of Dr. Shabbir T. Anik to the newly-created position of chief technical operations officer. Dr. Anik brings over 30 years of experience in pharmaceutical technology, drug development,...
Sutro Expands Senior Leadership Team with Addition of Chief Medical Officer and VP of Translational Pharmacology and Preclinical Development
SOUTH SAN FRANCISCO, Mar. 9, 2016 – Sutro Biopharma today announced the appointment of Arturo Molina, M.D., M.S., FACP as chief medical officer and Mark Lupher, Ph.D., as vice president of translational pharmacology and preclinical development (TP&PD). Both Dr....
Sutro Biopharma Receives the Pantheon 2015 DiNA Outstanding Partner Award by the California Life Sciences Association
SAN FRANCISCO, Nov. 18, 2015 /PRNewswire/ -- Sutro Biopharma today announced that it was awarded the Outstanding Partner Award, at the California Life Sciences Association (CLSA) annual Pantheon Ceremony 2015 Presenting DiNA Awards. Late last year, Sutro entered into...
Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management
SAN FRANCISCO, Aug. 4, 2015 - Sutro Biopharma today announced that it has appointed Nicki Vasquez, Ph.D., as vice president of alliance and project management. Dr. Vasquez will have a leadership role in the management of Sutro's collaborative partnerships and the...
SutroVax raises $22 million in Series A
Press release published by SutroVax, Vaccine Spin-off from Sutro Biopharma to Utilize Site-Specific Conjugation Technology Read more Vaccine Spin-off from Sutro Biopharma to Utilize Site-Specific Conjugation Technology South San Francisco, CA, July 23, 2015 –...
Production of Bispecific Antibodies in “Knobs-Into-Holes” Using a Cell-Free Expression System
Yiren Xu, John Lee, Cuong Tran, Tyler H Heibeck, Willie D Wang, Junhao Yang, Ryan L Stafford, Alexander R Steiner, Aaron K Sato, Trevor J Hallam, and Gang Yin, Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system mAbs 7:1,...